**CLAIMS:**

1. An antibody or an antigen binding fragment thereof, that specifically binds to an hOX40L epitope and comprises a heavy chain and a light chain and wherein:
    a. the heavy chain comprises a $V_H$ region having at least 85% identity to the amino acid sequence of SEQ ID No:34; and
    b. the light chain comprises a $V_L$ region having at least 85% identity to the amino acid sequence of SEQ ID No:48.

2. An antibody or antigen binding antigen binding fragment according to claim 1, wherein the antibody or antigen binding fragment comprises a $V_H$ domain which comprises the HCDR1 sequence of SEQ ID NO:36 or 42.

3. An antibody or antigen binding fragment according to claim 1 or claim 2, wherein the antibody or antigen binding fragment comprises a $V_H$ domain which comprises the HCDR2 sequence of SEQ ID NO:38 or 44.

4. An antibody or antigen binding fragment according to any preceding claim, wherein the antibody or antigen binding fragment comprises a $V_H$ domain which comprises the HCDR3 sequence of SEQ ID NO:40 or 46.

5. An antibody or antigen binding fragment according to any preceding claim, wherein the antibody or antigen binding fragment comprises a $V_H$ domain comprising an amino acid sequence of SEQ ID NO: 34.

6. An antibody or antigen binding fragment according to any preceding claim comprising a first copy and a second copy of said $V_H$ domain.

7. An antibody or antigen binding fragment according to claim 6, comprising a human gamma 4 constant region.

8. An antibody or antigen binding fragment according to claim 7, comprising a heavy chain constant region which is IgG4 PE.

9. An antibody or antigen binding fragment according to claim 8, comprising a heavy chain constant region of Seq ID No:128.

10. An antibody or antigen binding fragment according to any preceding claim, wherein the antibody or antigen binding fragment comprises a $V_L$ domain which comprises the LCDR1 sequence of SEQ ID No:50 or 56.

11. An antibody or antigen binding fragment according to any preceding claim, wherein the antibody or antigen binding fragment comprises a $V_L$ domain which comprises the LCDR2 sequence of SEQ ID NO:52 or 58.

12. An antibody or antigen binding fragment according to any preceding claim, wherein the antibody or antigen binding fragment comprises a $V_L$ domain which comprises the LCDR3 sequence of SEQ ID NO:54 or 60.

13. An antibody or antigen binding fragment according to any preceding claim, wherein the antibody or antigen binding fragment comprises a $V_L$ domain comprising an amino acid sequence of SEQ ID NO:48.

14. An antibody or antigen binding fragment according to any preceding claim comprising a first and a second copy of said $V_L$ domain.

15. An antibody or antigen binding fragment according to any preceding claim, wherein the antibody or antigen binding fragment comprises a kappa light chain.

16. An antibody or antigen binding fragment according to any preceding claim, wherein the antibody or antigen binding fragment comprises a kappa light chain comprising a constant region selected from the group consisting of the kappa light chain constant region amino acid sequences of Seq ID Nos: 136, 138, 140, 142 and 144.

17. An antibody or antigen binding fragment according to any preceding claim which is a fully human antibody.

18. An antibody according to any preceding claim, wherein the antibody comprises a heavy chain and a light chain, the heavy chain amino acid sequence consisting of the sequence of SEQ ID No:62 and the light chain amino acid sequence consisting of the sequence of SEQ ID No:64.

19. An antibody or antigen binding fragment according to any one of claims 1, 6 to 9, or 14 to 17, wherein the antibody or antigen binding fragment comprises a heavy chain variable region comprising an amino acid sequence consisting of the sequence of SEQ ID No:2, and a light chain variable region comprising an amino acid sequence consisting of the sequence of SEQ ID No:16.

20. An antibody or antigen binding fragment according to any preceding claim wherein the antibody or antigen binding fragment competes for binding to said hOX40L epitope with the antibody 02D10, which antibody 02D10 comprises a $V_H$ domain comprising the amino acid sequence consisting of the sequence of SEQ ID No:34 and a $V_L$ domain comprising the amino acid sequence consisting of the sequence of SEQ ID No:48.

21. An antibody or antigen binding fragment according to any preceding claim which specifically binds to said hOX40L epitope with a Kd of from 1nM to 10pM as determined by SPR.

22. An antibody or antigen binding fragment according to any preceding claim which specifically binds to rhesus monkey OX40L epitope with a Kd of from 10nM to 100pM as determined by SPR.

23. A pharmaceutical composition comprising an antibody or antigen binding fragment as defined in any one of claims 1 to 22, and a pharmaceutically acceptable excipient, diluent or carrier.

24. A pharmaceutical composition according to claim 23, formulated for parenteral administration selected from intravenous or sub-cutaneous administration.

25. A pharmaceutical composition according to claim 23 or claim 24, further comprising a further therapeutic agent independently selected from the group consisting of rapamycin (sirolimus), tacrolimus, ciclosporin, corticosteroids (e.g. methylprednisolone), methotrexate, mycophenolate mofetil, anti-CD28 antibodies, anti-IL12/IL-23 antibodies (e.g. ustekinumab), anti-CD20 antibodies (e.g.rituximab), anti-CD30 antibodies (e.g. brentuximab), CTLA4-Fc molecules (e.g. abatacept), CCR5 receptor antagonists (e.g. maraviroc), anti-CD40L antibodies, anti-VLA4 antibodies (e.g. natalizumab), anti-LFA1 antibodies, fludarabine, anti-CD52 antibodies (e.g. alemtuzumab), anti-CD45 antibodies, cyclophosphamide, anti-thymocyte globulins, anti-complement C5 antibodies (e.g. eculizumab), anti-a4b7 integrin antibodies (e.g. vedolizumab), anti-IL6 antibodies (e.g. tocilizumab), anti-IL2R antibodies (e.g. basilixumab), anti-CD25 antibodies (e.g. daclizumab), anti-TNFa / TNFa-Fc molecules (e.g. etanercept, adalimumab, infliximab, golimumab or certolizumab pegol) and Vorinostat.

26. A pharmaceutical composition according to any one of claims 23 to 25, or a kit comprising a pharmaceutical composition as defined in any one of claims 23 to 25, wherein the composition is for treating and/or preventing a hOX40L-mediated disease or condition selected from an autoimmune disease or condition, a systemic inflammatory disease or condition, or transplant rejection; for example inflammatory bowel disease (IBD), Crohn's disease, rheumatoid arthritis, transplant rejection, allogenic transplant rejection, graft-versus-host disease (GvHD), ulcerative colitis, systemic lupus erythematosus (SLE), diabetes, uveitis, ankylosing spondylitis, contact hypersensitivity, multiple sclerosis and atherosclerosis, in particular GvHD.

27. A pharmaceutical composition according to any one of claims 23 to 26, or kit according to claim 26, further comprising a label or instructions for use to treat and/or prevent said disease or condition in a human.

28. A pharmaceutical composition according to claim 27 or a kit according to claim 27, wherein the label or instructions comprise a marketing authorisation number (e.g., an FDA or EMA authorisation number).

29. A kit according to any one of claims 26 to 28, which comprises an IV or injection device that comprises the antibody or antigen binding fragment thereof.

30. An antibody or antigen binding fragment as defined in any one of claims 1 to 22 for use in therapy.

31. An antibody or antigen binding fragment according to claim 30, for use in treating or preventing a hOX40L-mediated disease or condition selected from an autoimmune disease or condition, a systemic inflammatory disease or condition, or transplant rejection.

32. An antibody or antigen binding fragment for the use according to claim 31, wherein the hOX40L-mediated disease or condition is selected from inflammatory bowel disease (IBD), Crohn's disease, rheumatoid arthritis, transplant rejection, allogenic transplant rejection, graft-versus-host disease (GvHD), ulcerative colitis, systemic lupus erythematosus (SLE), diabetes, uveitis, ankylosing spondylitis, contact hypersensitivity, multiple sclerosis and atherosclerosis.

33. An antibody or antigen binding fragment for the use according to claim 31, wherein the hOX40L-mediated disease or condition is dermatitis.

34. A nucleic acid that encodes the HCDR3 of an antibody or antigen binding fragment as defined in any one of claims 1 to 22.

35. A nucleic acid that encodes a $V_H$ domain and/or a $V_L$ domain of an antibody or antigen binding fragment as defined in any one of claims 1 to 22.

36. A nucleic acid according to claim 34, comprising a nucleotide sequence that is at least 80% identical to the sequence of SEQ ID NO: 33 and/or SEQ ID NO: 47.

37. A nucleic acid that encodes a heavy chain or a light chain of an antibody or antigen binding fragment as defined in any one of claims 1 to 22.

38. A vector comprising the nucleic acid as defined in any one of claims 34 to 37; optionally wherein the vector is a CHO or HEK293 vector.

39. A host comprising the nucleic acid as defined in any one of claims 34 to 37 or the vector as defined in claim 38.